In­flaRx wins FDA emer­gency use au­tho­riza­tion for Covid an­ti­body

In­flaRx’s mon­o­clon­al an­ti­body vilo­be­limab has re­ceived emer­gency use au­tho­riza­tion to treat crit­i­cal­ly ill Covid-19 pa­tients on in­va­sive me­chan­i­cal ven­ti­la­tion.

Vilo­be­limab, which will be sold un­der …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.